SEEK Group
Seekacure, trading as PepTcell Limited, is dedicated to improving human health through reformulating existing drugs, developing novel vaccines, and operating specialist clinics. Founded in 2004, the company focuses on innovative vaccine development, drug reformulation, and repurposing, with a strategic approach of developing medicines through early to mid-stage development before spinning them out into independent businesses.
Industries
Nr. of Employees
small (1-50)
Products
Lipid-formulated ibuprofen (enhanced ibuprofen formulation)
A lipid-formulated version of ibuprofen designed to increase bioavailability and modify distribution compared to standard formulations.
Lipid delivery platform for lipophilic molecules
A formulation platform using GRAS or pharmaceutically approved ingredients to enhance bioavailability and target distribution of lipophilic compounds; designed to be low-cost to manufacture and patent protected.
Targeted oral drug delivery platform for increased bioavailability and organ targeting
An oral delivery platform that leverages natural human biology to open an alternative uptake route, enabling increased systemic exposure and targeted delivery to organs such as CNS, respiratory system and tumors.
Broad-spectrum vaccines targeting conserved viral antigens
Vaccine candidates designed around conserved regions of viral proteins containing multiple T-cell epitopes to provide broad protection against rapidly mutating viruses and mosquito-borne pathogens.
Lipid-formulated ibuprofen (enhanced ibuprofen formulation)
A lipid-formulated version of ibuprofen designed to increase bioavailability and modify distribution compared to standard formulations.
Lipid delivery platform for lipophilic molecules
A formulation platform using GRAS or pharmaceutically approved ingredients to enhance bioavailability and target distribution of lipophilic compounds; designed to be low-cost to manufacture and patent protected.
Targeted oral drug delivery platform for increased bioavailability and organ targeting
An oral delivery platform that leverages natural human biology to open an alternative uptake route, enabling increased systemic exposure and targeted delivery to organs such as CNS, respiratory system and tumors.
Broad-spectrum vaccines targeting conserved viral antigens
Vaccine candidates designed around conserved regions of viral proteins containing multiple T-cell epitopes to provide broad protection against rapidly mutating viruses and mosquito-borne pathogens.
Services
Clinical provision of specialist, oncology-led metabolic therapy and other services to provide patients access to repurposed or reformulated medicines.
Collaborative licensing and partnering to integrate lipid and targeted oral delivery technologies into third-party therapeutic programmes.
Advancement of therapeutic and vaccine candidates through discovery, pre-clinical and early clinical development with the option to out-license or spin-out assets.
Clinical provision of specialist, oncology-led metabolic therapy and other services to provide patients access to repurposed or reformulated medicines.
Collaborative licensing and partnering to integrate lipid and targeted oral delivery technologies into third-party therapeutic programmes.
Advancement of therapeutic and vaccine candidates through discovery, pre-clinical and early clinical development with the option to out-license or spin-out assets.
Expertise Areas
- Drug reformulation and repurposing
- Lipid-based drug delivery
- Targeted oral drug delivery
- Vaccine design and antigen selection
Key Technologies
- Lipid-based formulation
- Targeted oral uptake platforms
- Conserved-region antigen design with T-cell epitope mapping
- Pre-clinical in vivo validation